Clinical trial · Interventional
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
The Efficacy and Safety of TACE Combined With Tilelizumab and Sorafenib in Treating BCLC Stage C HCC Patients: a Single-center, Single-arm, Prospective Clinical Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
According to the BCLC staging system treatment recommendation, systemic treatment is recommended for patients in BCLC stage C, and TACE and systemic treatment are recommended for patients in this stage. Studies have shown that TACE combined with sorafenib therapy has shown effectiveness in the treatment of advanced liver cancer, and PD-1 inhibitors have also shown effectiveness in the treatment of advanced liver cancer. Therefore, in order to improve the survival benefit of BCLC stage C liver cancer patients, this clinical study was designed to evaluate the effectiveness and safety of TACE combined with sorafenib and tislelizumab in the treatment of BCLC stage C liver cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| BCLC Stage C Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sorafenib | Drug | Sorafenib | ALIAS |
| TACE | Procedure | — | UNRESOLVED |
| Tilelizumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- TACE combined Tilelizumab and Sorafenib
- description
- TACE first combined Tilelizumab(240mg/3wks ivgtt） and Sorafenib （800mg/day orally)
- interventionNames
- Procedure: TACE
- Drug: Tilelizumab
- Drug: Sorafenib
Primary outcomes (1)
- measure
- 1-year survival rate
- timeFrame
- at 1 year after enrolled
- description
- 1-year survival rate assessed by Kaplan-Meier analysis
Secondary outcomes (4)
- measure
- Time to progression
- timeFrame
- at 12 weeks and up to 2 years after enrolled
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years * Child-Pugh score≤ 7 * HCC diagnosed by biopsy or by the noninvasive criteria of the Chinese Liver Cancer Guideline 2019 * the primary HCC being in BCLC C stage according to NCCN guideline * No previous systemic therapy for HCC Exclusion Criteria: * Diffuse HCC * Uncontrolled ascites of hepatic encephalopathy * Prior liver transplantation * Positive for human immunodeficiency virus * Active gastric or duodenal ulcer * Other uncontrolled comorbidities or malignancy
References
Publications (0)
Data not yet available